National Acalabrutinib Observational Study

Trial Identifier: D8220R00045
Sponsor: AstraZeneca
NCTID:: NCT05437250
Start Date: September 2022
Primary Completion Date: November 2026
Study Completion Date: November 2026
Condition: CLL (Chronic Lymphocytic Leukemia)

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
France Avignon, France
France Bourg en Bresse, France
France GRENOBLE, France
France GRENOBLE, France
France GRENOBLE, France
France GRENOBLE, France
France GRENOBLE, France
France GRENOBLE, France
France GRENOBLE, France
France GRENOBLE, France
France GRENOBLE, France
France GRENOBLE, France
France GRENOBLE, France
France GRENOBLE, France
France GRENOBLE, France
France GRENOBLE, France
France GRENOBLE, France
France GRENOBLE, France
France GRENOBLE, France
France GRENOBLE, France
France GRENOBLE, France
France GRENOBLE, France
France GRENOBLE, France
France GRENOBLE, France
France GRENOBLE, France
France GRENOBLE, France
France GRENOBLE, France
France GRENOBLE, France
France GRENOBLE, France
France GRENOBLE, France
France GRENOBLE, France
France GRENOBLE, France
France GRENOBLE, France
France GRENOBLE, France
France GRENOBLE, France
France GRENOBLE, France
France GRENOBLE, France
France GRENOBLE, France
France GRENOBLE, France
France GRENOBLE, France
France GRENOBLE, France
France GRENOBLE, France
France GRENOBLE, France
France GRENOBLE, France
France GRENOBLE, France
France GRENOBLE, France
France GRENOBLE, France
France GRENOBLE, France
France GRENOBLE, France
France GRENOBLE, France
France GRENOBLE, France
France GRENOBLE, France
France GRENOBLE, France
France GRENOBLE, France
France GRENOBLE, France
France GRENOBLE, France
France GRENOBLE, France
France GRENOBLE, France
France GRENOBLE, France
France GRENOBLE, France
France GRENOBLE, France
France La Tronche, France
France Lens, France